InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,010.60
(
0.87%
)
US TECH 100
16,752.80
(
0.00%
)
Dow Jones
38,239.98
(
0.67%
)
Brent Oil
86.56
(
0.17%
)
Bitcoin
66,368.67
(
-0.73%
)
Post# of 10
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Swe_bio_

Send PM Follow Ignore
Followers 1
Posts 13
Boards Moderated 0
Alias Born 05/13/2017

Swe_bio_

Re: None

Wednesday, 11/15/2017 8:21:09 PM

Wednesday, November 15, 2017 8:21:09 PM

Post# of 10
Saniona AB: Saniona publishes its interim report for the third quarter 2017 (GlobeNewswire)
2017-11-15 08:00

"Within the next two years, we will have the opportunity to initiate clinical studies in several metabolic diseases including obesity, diabetes and fatty liver/NASH. As these studies tend to be costly, we envision finding partners prior to initiating Phase 3 clinical trials. Tesomet is also potentially relevant for various eating disorders."

http://hugin.info/172499/R/2149075/824689.pdf
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up